Formycon Brand
“This licensing deal for the MENA region represents the start of the commercial partnering activities for our Keytruda® biosimilar candidate. Further agreements for additional regions and countries shall follow in due time. With MS Pharma, we are leveraging the well-established excellent collaboration that has already been successfully implemented for our biosimilars FYB201, FYB202, and FYB203. MS Pharma is a strong player that can sustainably improve access to this important cancer drug across the MENA region. FYB206 is currently approaching the end of its clinical development phase, and we expect results for the primary endpoint in the first quarter of 2026,” stated Nicola Mikulcik, CBO of Formycon AG.
“Extending our partnership with Formycon for FYB206 (pembrolizumab), is a strategically important milestone for MS Pharma. This collaboration not only strengthens our position as a leader in biosimilars across the MENA region but also demonstrates our commitment to expanding access to innovative cancer therapies. Leveraging Formycon’s scientific expertise with our established local capabilities and our advanced manufacturing facility in Saudi Arabia, we are well-positioned to deliver high-quality biosimilars that meet the needs of patients and healthcare systems in the MENA region,” commented Kalle Känd, CEO of MS Pharma.
Upon signature of the settlement, Formycon will obtain an prematurely remuneration and will probably be eligible for additional bills contingent at the fulfillment of positive construction and regulatory milestones, Formycon will additional obtain a vital percentage of the gross earnings generated within the area.
MS Pharma will proceed to give a contribution to larger remedy availability whilst supporting nationwide methods all for localization, resilience, and sustainable get entry to to oncology care. This collaboration reinforces MS Pharma’s function as a long-term spouse to governments and healthcare establishments around the area, serving to handle continuity and high quality of deal with sufferers.
Pembrolizumab is a humanized monoclonal antibody that belongs to the crowd of immune checkpoint inhibitors and is used to regard various tumors. With its large vary of indications in oncology and international gross sales of US$ 29.5 billion in 2024[2], Keytruda® is these days one of the most international’s best-selling medication. Within the MENA area, estimated gross sales reached roughly US$ 240 million[3], positioning it because the highest-selling biologic within the area and underscoring the really extensive oncology call for and marketplace attainable throughout MENA.
About Formycon:
Formycon AG (FSE: FYB) is a number one, impartial developer of top quality biosimilars, follow-on merchandise of biopharmaceutical drugs. The corporate specializes in treatments in ophthalmology, immunology, immuno-oncology and different key illness spaces, masking virtually all the price chain from technical construction via medical trials to approval via the regulatory government. For commercialization of its biosimilars, Formycon is determined by robust, well-trusted and long-term partnerships international. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars in the marketplace. Any other biosimilar, FYB203/aflibercept, has been authorized via the FDA, EMA, and MHRA. 4 pipeline applicants – together with FYB208/dupilumab – are these days in construction. With its biosimilars, Formycon is making crucial contribution to offering as many sufferers as conceivable with get entry to to extremely efficient and inexpensive drugs.
Formycon AG is headquartered in Munich, indexed within the Top Usual of the Frankfurt Inventory Trade: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is a part of the SDAX variety index. Additional knowledge can also be discovered at: https://www.formycon.com.
About MS Pharma:
MS Pharma is a number one regional pharmaceutical corporate within the MENA area, focusing on the improvement, manufacturing, and distribution of a large portfolio of generic and biologic treatments. Situated for fast enlargement, the corporate operates 5 production amenities throughout Jordan, Algeria, and Saudi Arabia – house to a newly introduced biologics plant, all serving the wider MENA marketplace. Headquartered in Amman, Jordan, with control places of work in Zug, Switzerland, MS Pharma employs over 2,000 other people throughout 12 nations. For more info, please seek advice from: www.mspharma.com.
About Biosimilars:
Since their advent within the Eighties, biopharmaceutical medication have revolutionized the remedy of great and persistent illnesses. Via 2032, many of those medication will lose their patent coverage – together with 45 blockbusters with an estimated general annual international turnover of greater than 200 billion US bucks. Biosimilars are successor merchandise to biopharmaceutical medication for which marketplace exclusivity has expired. They’re authorized in extremely regulated markets such because the EU, the United States, Canada, Japan and Australia according to strict regulatory procedures. Biosimilars create festival and thus give extra sufferers get entry to to biopharmaceutical treatments. On the similar time, they cut back prices for healthcare techniques. International gross sales of biosimilars these days quantity to round 21 billion US bucks. Analysts think that gross sales may just upward push to over 74 billion US bucks via 2030.
Disclaimer:
This press unlock might include forward-looking statements and knowledge that are in line with Formycon’s present expectancies and likely assumptions. Quite a lot of recognized and unknown dangers, uncertainties and different components may just result in subject matter variations between the true long run effects, monetary state of affairs, efficiency of the corporate, construction of the goods and the estimates given right here. Such recognized and unknown dangers and uncertainties contain, amongst others, the analysis and construction, the regulatory approval procedure, the timing of the movements of regulatory our bodies and different governmental government, medical effects, adjustments in rules and laws, product high quality, affected person protection, patent litigation, contractual dangers and dependencies from 3rd events. With admire to pipeline merchandise, Formycon AG does no longer supply any illustration, warranties or another promises that the goods will obtain the vital regulatory approvals or that they’re going to turn out to be commercially exploitable and/or a success. Formycon AG assumes no legal responsibility to replace those forward-looking statements or to proper them in case of traits which range from the ones expected. This report neither constitutes an be offering to promote nor a solicitation of an be offering to shop for or subscribe for securities of Formycon AG. No public providing of securities of Formycon AG will probably be made neither is a public providing meant. This report and the ideas contained therein will not be dispensed in or into america of The usa, Canada, Australia, Japan or another jurisdictions, during which such be offering or such solicitation could be prohibited. This report does no longer represent an be offering for the sale of securities in america.
SOURCE MS Pharma
